Beclomethasone/formoterol in the management of COPD: A randomised controlled trial

Respiratory Medicine

Volumn 104, Issue 12, 2010, Pages 1858-1868

  Calverley, P M A ^a   Kuna, P ^b   Monso E ^c   Costantini, M ^d   Petruzzelli, S ^d   Sergio, F ^d   Varoli, G ^d   Papi, A ^e   Brusasco, V ^f  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d CHIESI FARMACEUTICI S P A   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

Chronic obstructive airways disease; COPD; Exacerbations; Inhaled corticosteroid; Long acting 2 agonist; Lung function

Indexed keywords

ANTIBIOTIC AGENT; BECLOMETASONE; BECLOMETHASONE PLUS FORMOTEROL; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; FOSTER; HYDROCORTISONE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAPHY; EMERGENCY CARE; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOLTER MONITORING; HOSPITALIZATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QT INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; VITAL SIGN; WALKING;

ALBUTEROL; BECLOMETHASONE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 78650026603     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.09.008     Document Type: Article

References (32)

1. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
2. S. Spencer, P.M. Calverley, P.S. Burge, and P.W. Jones Impact of preventing exacerbations on deterioration of health status in COPD Eur Respir J 23 2004 698 702
3. K.F. Rabe, S. Hurd, and A. Anzueto Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 176 2007 532 555
4. C.R. Jenkins, P.W. Jones, and P.M. Calverley Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Respir Res 10 2009 59
5. J.C. Mak, M. Nishikawa, H. Shirasaki, K. Miyayasu, and P.J. Barnes Protective effects of a glucocorticoid on downregulation of pulmonary beta-2 adrenergic receptors in vivo J Clin Invest 96 1995 99 106
6. J.N. Baraniuk, M. Ali, and D. Brody Glucocorticosteroids induce beta2-adrenergic receptor function in human nasal mucosa Am J Respir Crit Care Med 155 1997 704 710
7. O. Eickelberg, M. Roth, and R. Lorx Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells J Biol Chem 274 1999 1005 1010
8. P.M. Calverley, J.A. Anderson, and B. Celli Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
9. L.M. Fabbri, G. Nicolini, D. Olivieri, and A. Papi Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives Expert Opin Pharmacother 9 2008 479 490
10. J. Bousquet, G. Poli, and Acerbi Systemic exposure and implications for lung deposition with extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination Clin Pharmacokinet 48 2009 347 358
11. M. Contoli, J. Bousquet, and L.M. Fabbri The small airways and distal lung compartment in asthma and COPD: a time for reappraisal Allergy 65 2010 141 151
12. W. De Backer, A. Devolder, and G. Poli Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients J Aerosol Med Pulm Drug Deliv 23 2010 137 148
13. P.J. Barnes Small airways in COPD N Eng J Med 350 2004 2635 2637
14. A. Papi, P. Paggiaro, G. Nicolini, A.M. Vignola, and L.M. Fabbri Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma Allergy 62 2007 1182 1188
15. A. Papi, P.L. Paggiaro, G. Nicolini, A.M. Vignola, and L.M. Fabbri Becolmethasone/formoterol versus budesonide/formoterol combination therapy in asthma Eur Respr J 29 2007 682 689
16. M.R. Miller, J. Hankinson, and V. Brusasco Standardisation of spirometry Eur Respir J 26 2005 319 338
17. F. Sciurba, G.J. Criner, and S.M. Lee Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length Am J Respir Crit Care Med 167 2003 1522 1527
18. B.R. Celli, C.G. Cote, and J.M. Marin The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med 350 2004 1005 1012
19. W. Szafranski, A. Cukier, and A. Ramirez Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 21 2003 74 81
20. P. Calverley, W. Boonsawat, Z. Cseke, N. Zhong, S. Petersen, and H. Olsson Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Eur Respir J 22 2003 912 919 (Pubitemid 37540641)
21. P. Calverley, R. Pauwels, and J. Vestbo Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 2003 449 456
22. B.R. Celli, N.E. Thomas, and J.A. Anderson Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Results from the TORCH study Am J Respir Crit Care Med 178 2008 332 338
23. M. Cazzola, W. Macnee, and F.J. Martinez Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 2008 416 468
24. R.L. Sorkness, E.R. Bleecker, and W.W. Busse Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation J Appl Physiol 104 2008 394 403
25. 1 between patients with asymptomatic bronchial hyperresponsiveness and mild asthma Chest 132 2007 106 111
26. P.M. Calverley, K.F. Rabe, U.M. Goehring, S. Kristiansen, L.M. Fabbri, and F.J. Martinez Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials Lancet 374 2009 685 694
27. D.P. Tashkin, B. Celli, and S. Senn A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
28. J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, and R.A. Stockley The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26
29. J.R. Hurst, G.C. Donaldson, J.K. Quint, J.J. Goldring, R. Baghai-Ravary, and J.A. Wedzicha Temporal clustering of exacerbations in chronic obstructive pulmonary disease Am J Respir Crit Care Med 179 2009 369 374
30. J. Vestbo, J.A. Anderson, and P. Calverley Adherence to inhaled therapy, mortality, and hospital admission in COPD Thorax 64 2009 939 943
31. F. Garcia-Rio, V. Lores, and O. Mediano Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation Am J Respir Crit Care Med 180 2009 506 512
32. D.A. Sin, D. Tashkin, and X. Zhang Budesonide and the risk of pneumonia: a meta-analysis of individual patient data Lancet 374 2009 712 719